UroGen Pharma Ltd. (URGN)

NASDAQ · Pharmaceuticals & Biotech · Pharmaceutical Preparations

Price

$41.23

Day

-0.96%

Market cap

$2.02B

Close 2026-09-24.

The company

Overview We are a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. We have developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based technology that has the potential to improve therapeutic profiles of existing drugs. Our technology is designed to enable longer exposure of urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our approved products Jelmyto (mitomycin) for pyelocalyceal solution and Zusduri (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer (“low-grade UTUC”) and recurrent low-grade intermediate risk non-muscle invasive bladder cancer (“low-grade intermediate risk NMIBC”), respectively. In addition, our immuno-uro-oncology pipeline includes UGN-501 (formerly known as ICVB-1042), a next-generation investigational oncolytic virus.

From Item 1: Overview.

By product & service

• Jelmyto — 86%
• Zusduri — 14%

Institutional holders

Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.

• RTW INVESTMENTS, LP — $167.22M
• MORGAN STANLEY — $93.58M
• Kynam Capital Management, LP — $89.58M
• Jefferies Financial Group Inc. — $80.95M
• BlackRock, Inc. — $73.57M
• AMERICAN CENTURY COMPANIES INC — $62.03M
• ACORN CAPITAL ADVISORS, LLC — $61.58M
• Point72 Asset Management, L.P. — $56.14M

Insider trades

Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.

• Schoenberg Mark (Chief Medical Officer) sold 871 shares at $42.92 on 2026-09-08
• Smith Jason Drew (General Counsel) sold 1,519 shares at $42.54 on 2026-09-08
• Schoenberg Mark (Chief Medical Officer) sold 60,677 shares at $47.05 on 2026-08-20
• Schoenberg Mark (Chief Medical Officer) sold 10,000 shares at $40.00 on 2026-07-09
• Schoenberg Mark (Chief Medical Officer) sold 10,000 shares at $35.01 on 2026-06-22
• Schoenberg Mark (Chief Medical Officer) sold 5,222 shares at $27.30 on 2026-06-08

Recent filings

• 144 — 2026-09-09
• 144 — 2026-09-09
• 4 — 2026-09-09
• 4 — 2026-09-09
• 4 — 2026-08-28
• 4 — 2026-08-24
• 144 — 2026-08-20
• 8-K — 2026-08-20
• SCHEDULE 13G/A — 2026-08-12
• 10-Q — 2026-08-05